Treatment of chronic active hepatitis and other liver diseases with corticosteroid agents.
The term chronic active hepatitis covers aetiologically different conditions with similar histological features. Autoimmune chronic active hepatitis - the type that was described originally - is the only type which responds well to prednisolone therapy. Autoimmune chronic active hepatitis can be differentiated from other types by serological and other markers. Treatment with prednisolone should be given for at least two years, with adjustment of dosage according to the serum levels of aspartate transaminase; maintenance does should be 8-12 mg a day. Azathioprine (50-100 mg a day) may be given concurrently as a corticosteroid-sparing agent. Prednisolone therapy in patients with autoimmune chronic active hepatitis enhances the quality of life and survival is prolonged greatly; currently the survival rate after 10 years for prednisolone-treated cases is at least 70%. Prednisolone is not effective in hepatitis B-associated chronic active hepatitis and may be deleterious. In cryptogenic chronic active hepatitis, in which markers of autoimmunity or hepatitis B viral infection are lacking, a trial of prednisolone therapy may be given for three months, and continued only if the indices of disease activity indicate a response. Corticosteroid agents have not proved of benefit in other liver diseases, including alcoholic hepatitis and acute liver failure, and a beneficial effect in primary biliary cirrhosis is yet to be established.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use; D006519:Hepatitis, Alcoholic / Q000188:drug therapy; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D011239:Prednisolone; D001379:Azathioprine